Thromboembolism and Immune Checkpoint Blockade in Cancer Patients: An Old Foe for New Research.
Auteurs : Langouo Fontsa M, Aiello MM, Migliori E, Scartozzi M, Lambertini M, Willard-Gallo K, Solinas C Jaar : 2022 Journal : Target Oncol
Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis.
Auteurs : Martins-Branco D, Nader-Marta G, Tecic Vuger A, Debien V, Ameye L, Brandão M, Punie K, Loizidou A, Willard-Gallo K, Spilleboudt C, Awada A, Piccart M, de Azambuja E Jaar : 2022 Journal : J Cancer Res Clin Oncol
Biomarkers and immunotherapy: where are we?
Auteurs : Langouo Fontsa M, Padonou F, Willard-Gallo K Jaar : 2022 Journal : Curr Opin Oncol
Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial.
Auteurs : Schwarze JK, Garaud S, Jansen YJL, Awada G, Vandersleyen V, Tijtgat J, de Wind A, Kristanto P, Seremet T, Willard-Gallo K, Neyns B Jaar : 2022 Journal : Cancers (Basel)
Characterization of Immunoactive and Immunotolerant CD4+ T Cells in Breast Cancer by Measuring Activity of Signaling Pathways That Determine Immune Cell Function.
Auteurs : Wesseling-Rozendaal Y, van Doorn A, Willard-Gallo K, van de Stolpe A Jaar : 2022 Journal : Cancers (Basel)